Quantum BioPharma Ltd. (NASDAQ: QNTM) has achieved a significant regulatory milestone with the U.S. Food and Drug Administration's clearance of its Investigational New Drug (IND) application for Lucid-MS, the company's patented new chemical entity for multiple sclerosis. The clearance permits Quantum BioPharma to initiate a randomized, double-blind, placebo-controlled Phase 2 clinical trial in people with multiple sclerosis, advancing the drug candidate from preclinical evaluation into human testing.
The IND submission, approximately 15,000 pages in length, included comprehensive pharmacology, toxicology and manufacturing data. This extensive dataset was sufficient for the FDA to allow the company to move directly into a Phase 2 trial, bypassing the need for a separate Phase 1 safety study in healthy volunteers. That streamlined path is uncommon for a micro-cap biotech and could materially shorten the timeline to potential regulatory approval, should the trial succeed.
Lucid-MS has shown in preclinical models the ability to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Myelin is the protective sheath that surrounds nerve fibers; its destruction leads to the neurological symptoms characteristic of MS, including muscle weakness, coordination problems and vision loss. A therapy that can both stop and reverse myelin damage would represent a fundamental advance over existing treatments, which primarily modulate the immune system rather than repair existing damage.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of Lucid-MS. The company also invented UNBUZZD, an over-the-counter product spun out to Unbuzzd Wellness Inc., in which Quantum retains a 19.84% ownership stake as of March 31, 2026, along with royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity.
For investors, the FDA clearance de-risks a key regulatory hurdle and provides a clear catalyst: the launch of a Phase 2 trial. Positive results could position Lucid-MS as a first-in-class remyelinating therapy, addressing a major unmet need in multiple sclerosis. The company's newsroom at https://nnw.fm/QNTM provides ongoing updates. To view the full press release, visit https://nnw.fm/E5nJp.
NetworkNewsWire, a specialized communications platform focused on financial news and content distribution, featured Quantum BioPharma in a NetworkNewsAudio Audio Press Release titled “A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach.” More information is available at https://www.NetworkNewsWire.com.
